Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07109323 | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM | recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106749 | CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT05841550 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07072325 | Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers | not yet recruiting | Phase 1 | 9 | West China HospitalOTHER | 0 | Aug 3, 2025 | clinicaltrials |
| NCT07101601 | Study of DM5167 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 58 | DIGMBIOINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05735496 | Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers | active not recruiting | Phase 1 | 219 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07025850 | Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT07096882 | SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection | recruiting | Phase 1 | 22 | Cytocraft Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07097207 | Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06838832 | Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092748 | A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06695026 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | Rznomics, Inc.OTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06710158 | Study of SC-102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 120 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 84 | Cancer Research UKOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 | 67 | MedImmune LLCINDUSTRY | 4 | Jul 25, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07032298 | A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07063329 | Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | not yet recruiting | Phase 1 / Phase 2 | 108 | Avistone Pharmaceutical（Ningbo）Co., LTD.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | recruiting | Phase 1 / Phase 2 | 60 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05540899 | Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer | active not recruiting | Phase 1 | 14 | American College of RadiologyOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07066397 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL | recruiting | Phase 1 | 12 | TriArm Therapeutics (Taiwan) LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07076823 | Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077356 | Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077369 | WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT06020885 | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. | active not recruiting | Phase 1 | 18 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072169 | A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) | recruiting | Phase 1 | 56 | Ruijin HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study | recruiting | Phase 1 / Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT06329973 | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer | recruiting | Phase 1 / Phase 2 | 70 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06963814 | Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 252 | HC Biopharma Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 14 | Jul 16, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 7, 2025source: clinicaltrials